| Budget Amount *help |
¥23,530,000 (Direct Cost: ¥18,100,000、Indirect Cost: ¥5,430,000)
Fiscal Year 2017: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2016: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2015: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2014: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
|
|---|
| Outline of Final Research Achievements |
We developed sarcoma cell lines showing resistance to anticancer drugs such as doxorubicin, pazopanib and eribulin, which were widely used for bone and soft tissue sarcomas. The established drug resistant cell lines were used to analyze genes and proteins involved in drug resistance. Among them, the research using the pazopanib-resistant cell line of synovial sarcoma has succeeded in elucidating the mechanism of drug resistance and published in an English journal. In addition, we have found that HIF1α, a hypoxia-inducible factor involved in drug resistance, is a poor prognostic factor in malignant peripheral nerve sheath tumors and can be a therapeutic target. In leiomyosarcoma, we found that acquisition of drug resistance to eribulin involves overexpression of Class III β-tubulin and published in an English journal.
|
